Tirzepatide Linked to Lower Glaucoma Risk
Tirzepatide initiation in type 2 diabetes mellitus was associated with a significantly lower risk of primary open-angle glaucoma, ocular hypertension, and need for glaucoma treatment compared with selective glucagon-like peptide-1 receptor agonists.